| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Zenas BioPharma, Inc.
13D/A
ZBIO · 98937L105
|
4.9% |
10/14/2025
Event 10/9/2025
|
||||
| Longitude Capital Partners IV, LLC | 3.4% | |||||
| Longitude Venture Partners IV, L.P. | 3.4% | |||||
| Longitude Prime Partners, LLC | 1.4% | |||||
| Longitude Prime Fund, L.P. | 1.4% | |||||
| Patrick G. Enright | 4.9% | |||||
| Juliet Tammenoms Bakker | 4.9% | |||||
|
CG Oncology, Inc.
13D
CGON · 156944100
|
6.0% |
9/18/2025
Event 9/11/2025
|
||||
| Longitude Capital Partners IV, LLC | 4.1% | |||||
| Longitude Venture Partners IV, L.P. | 4.1% | |||||
| Longitude Prime Partners, LLC | 1.9% | |||||
| Longitude Prime Fund, L.P. | 1.9% | |||||
| Patrick G. Enright | 6.0% | |||||
| Juliet Tammenoms Bakker | 6.0% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Lexeo Therapeutics, Inc.
13G/A
LXEO · 52886X107
|
3.8% |
11/14/2025
Event 9/30/2025
|
||||
| Longitude Capital Partners IV, LLC | 3.8% | |||||
| Longitude Venture Partners IV, L.P. | 3.8% | |||||
| Patrick G. Enright | 3.8% | |||||
| Juliet Tammenoms Bakker | 3.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.